

Journal of Child and Adolescent Psychopharmacology: <https://mc.manuscriptcentral.com/jcap>

**Letter to the Editor: Beyond crisis, prolonged effectiveness  
of ketamine in adolescents with treatment-refractory  
depression**

Journal:	<i>Journal of Child and Adolescent Psychopharmacology</i>
Manuscript ID	CAP-2025-0137.R1
Manuscript Type:	Letter to the Editor
Date Submitted by the Author:	n/a
Complete List of Authors:	DUSI, Laura; University of Brescia, Department of Clinical and Experimental Sciences HOFMAN, Alice; UPMC Faculte de Medecine Site Pitie-Salpetriere, Child and adolescent psychiatry CHERIGUI-MEFTOUT, Nawel; UPMC Faculte de Medecine Site Pitie-Salpetriere, Child and adolescent psychiatry FRANCESCHINI-MANDEL, Anne; UPMC Faculte de Medecine Site Pitie-Salpetriere, Child and adolescent psychiatry BRUNELLE, Julie; University Hospital Pitié Salpêtrière, Department of Child and Adolescent Psychiatry MAUNY, Philippe; University Hospital Pitié Salpêtrière, Department of Child and Adolescent Psychiatry LE BOUEDEC, Marine; UPMC Faculte de Medecine Site Pitie-Salpetriere, Child and adolescent psychiatry Consoli, Angéle; Pitié-Salpêtrière hospital, Department of Child and Adolescent Psychiatry Cohen, David; Pitié Salpêtrière, Department of Child and Adolescent Psychiatry DEL CUL, Antoine; Pitié-Salpêtrière University Hospital, Department of psychiatry Hanin, Cyril; UPMC Faculte de Medecine Site Pitie-Salpetriere, Child and adolescent psychiatry Benarous, Xavier; UPMC Faculte de Medecine Site Pitie-Salpetriere, Child and adolescent psychiatry
Keyword:	Major Depressive Disorder, Antidepressants, Affective (Mood) Disorders
Manuscript Keywords (Search Terms):	ketamine, treatment-refractory depression, resistant depression, adolescent, pediatric population
Abstract:	[no required for Letter to the Editor]

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## AUTHOR DECLARATION TEMPLATE

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from ([xavier.benarous@aphp.fr](mailto:xavier.benarous@aphp.fr))

Signed by all authors as follows:

Laura DUSI

Alice HOFMAN

Nawel CHERIGUI-MEFTOUT

Anne FRANCESCHINI-MANDEL

Julie BRUNELLE

Philippe MAUNY

Marine LE BOUEDEC

Angèle CONSOLI

David COHEN

Antoine DELCUL

Cyril HANIN

Xavier BENAROUS

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review Only/Not for Distribution

1  
2  
3 **Letter to the Editor: Beyond crisis, prolonged effectiveness of ketamine in adolescents**  
4  
5  
6 **with treatment-refractory depression**  
7

8  
9 Laura DUSI<sup>1</sup>, Alice HOFMAN<sup>2</sup>, Nawel CHERIGUI-MEFTOUT<sup>2</sup>, Anne FRANCESCHINI-  
10 MANDEL<sup>2</sup>, Julie BRUNELLE<sup>2</sup>, Philippe MAUNY<sup>2</sup>, Marine LE BOUEDEC<sup>2</sup>, Angèle CONSOLI<sup>2,3</sup>,  
11 David COHEN<sup>2,4</sup>, Antoine DELCUL<sup>5</sup>, Cyril HANIN<sup>2</sup>, Xavier BENAROUS<sup>2,3</sup>  
12

13  
14 <sup>1</sup>Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

15 <sup>2</sup> Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière University Hospital, AP-HP.Sorbonne  
16 Université, Paris, France

17 <sup>3</sup> INSERM UMR-S 1136, Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLesp), Social  
18 Epidemiology, Mental Health and Addictions (ESSMA) team, Paris, France

19 <sup>4</sup> CNRS UMR 7222, Institute for Intelligent Systems and Robotics, Sorbonne University, Paris, France

20 <sup>5</sup> Department of Adult Psychiatry, Pitié-Salpêtrière University Hospital, APHP.Sorbonne Université, Paris,  
21 France

22  
23 Running head: Ketamine depression

24  
25 Type of article: Letters to the Editor

26  
27 **CORRESPONDING AUTHOR:**

28 Xavier Benarous, M.D., Ph.D.

29 Child and Adolescent Psychiatry Department

30 Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université

31 47-83 boulevard de l'Hôpital, 75013 Paris, France

32 Tel: + 33 1 42 16 23 63

33 Fax: + 33 (0) 1 42 16 19 03

34 [xavier.benarous@aphp.fr](mailto:xavier.benarous@aphp.fr)  
35

36 **Declarations**

37 **Ethics approval and consent to participate**

38 Written informed consent was obtained from the patient to publish any potentially identifiable images or data in  
39 this article. This manuscript adheres to the CARE guidelines for publishing case reports, with the completed  
40 CARE 2013 checklist attached as Supplementary Materials. Ethical committees / Internal Review Boards: not  
41 applicable

42 **Consent for Publication**

43 Written informed consent for publication was obtained from the parents and is available upon request.

44 **Availability of data and materials**

45 Data sharing does not apply to this article, as no datasets were generated during the current study.

46 **Competing interests**

47 The authors declare that they have no competing interests.

48 **Funding**

49 This research received no specific grant support.

50 **Authors' contributions**

51 LD, CH, DC and XB conceptualized and designed the study, drafted the initial manuscript, and reviewed and  
52 revised the manuscript. AH, NCM, AFM, JB, AC, PM, MLB, and AD followed the patient and contributed to  
53 data acquisition. All authors approved the final manuscript as submitted and agreed to be accountable for all  
54 aspects of the work.

55 **Acknowledgements**

56 The authors would like to thank the patient and his parents for their cooperation as well as all the staff of the care  
57 unit for their support and assistance during the patient's follow-up.

58 **Clinical trial number**

59 Not applicable  
60

1  
2  
3 **Letter to the Editor: Beyond crisis, prolonged effectiveness of ketamine in adolescents**  
4  
5 **with treatment-refractory depression**  
6  
7  
8

9 The clinical, functional, and economic burden associated with treatment-refractory  
10 depression (TRD) in adolescence makes it urgent to develop new pharmacological options.  
11 Unlike in adult psychiatry, the evidence supporting the use of ketamine in adolescents for this  
12 indication remains relatively limited, while most studies focus on suicidal crises and short-  
13 term outcomes (Dwyer et al. 2021; Smith-Apeldoorn et al. 2022). Dwyer et al. (2017)  
14 published the only report of an 8-week intravenous ketamine protocol, showing sustained  
15 clinical benefit over 30 weeks. The current clinical vignettes illustrate the prolonged  
16 effectiveness and safety of ketamine for two adolescents with TRD.  
17  
18

19 Patient A was a 14-year-old adolescent assigned female at birth and identifies as male  
20 (AFAB). A family history of type 1 bipolar disorder was reported in two family members. He  
21 was referred for a severe TRD with no melancholic or psychotic features, with an onset two  
22 years ago, with severe non-suicidal self-injury (NSSI) requiring orthopedic intervention, and a  
23 suicidal attempt by jumping from his school building. Intravenous ketamine was administered  
24 at a dose of 0.25 mg/kg, subsequently increased to 0.5 mg/kg, resulting in a total of ten  
25 treatments (Figure 1). A rapid clinical improvement was observed following the initial  
26 infusion, reflected by a 45% reduction in MADRS score and complete remission by day 16.  
27 Over the next 5 months, the patient continued to show a partial decrease in depressive  
28 symptoms over this period, estimated at approximately 40–50% by the referent psychiatrist.  
29  
30  
31

32 Patient B was a 17-year-old male. The biological parents of both siblings died when the  
33 patient was 8 months old. Developmental history found a delay in language acquisition and  
34 Attention-Deficit/Hyperactivity Disorder. The patient was initially referred for a suicidal and  
35 rage crisis, with a diagnosis of TRD with melancholic features. The patient received a total of  
36 eight ketamine infusions. A marked clinical response was observed following the first  
37 infusion, with a 77% reduction in MADRS and complete remission by day 43. One year after  
38 discharge, the patient had not required any further hospitalizations or emergency  
39 consultations. Pharmacological treatment was well tolerated, and no adverse effects were  
40 reported.  
41  
42

43 [Insert Figure 1 about here]  
44

45 As the antidepressant effect of ketamine was-is regarded as rapid and often transient, its  
46 application beyond the scope of short-term suicidal crisis management remains less well  
47 explored, especially in adolescents. In adults, roughly half of 71 patients who completed a  
48 finite course of repeated IV ketamine maintained their improvement at nine months, with  
49 most relapses occurring within the first two weeks (Li et al. 2022).  
50  
51

52 For both patients here, a rapid and complete remission of depressive symptoms was  
53 observed. More importantly for our perspective, both patients maintained complete remission  
54 at six months (patient A) and one year (patient B) following the last ketamine  
55 perfusion/infusion. The treatment was well tolerated, and no relapse was observed in the  
56 weeks following the end of the administration. Such preliminary findings stress the potential  
57 for sustained long-term clinical benefit of ketamine IV for adolescents with TRD, which  
58 represents considerable promise for these patients.  
59  
60

1  
2  
3  
4  
5  
6 **FIGURE 1. Decrease in MADRS score and PRN medication during patients' ketamine**  
7 **treatment**

8 *Note.* PRN was mainly prescribed to reduce agitation, sleep difficulties, and irritability-  
9 related aggressive behaviors. For patient A, after discussion with our local expert centre for  
10 bipolar disorder (BD), considering the high risk of BD in patient A (i.e., positive family  
11 history of BD, behavioral activation symptoms after SSRI prescription) we decide to not  
12 prescribe another SSRI, and to go directly to ketamine with associated prescriptions of mood  
13 stabilizers. Two months after discharge, he went to emergency department following an  
14 episode of NSSI in a context of acute stress, crisis management interventions helped the  
15 patient to quickly return to baseline functioning.  
16

17  
18  
19 **SUPPLEMENTARY MATERIALS.**

20 **FIG S1. Detailed time line of treatment received by patient A.**

21 **FIG S2. Detailed time line of treatment received by patient B**  
22

23  
24 **REFERENCES**

- 25  
26 Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH: Ketamine as a Treatment for  
27 Adolescent Depression: A Case Report. J Am Acad Child Adolesc Psychiatry 56:352-354,  
28 2017.  
29 Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Coulores  
30 K, Sanacora G, Bloch MH: Efficacy of Intravenous Ketamine in Adolescent Treatment-  
31 Resistant Depression: A Randomized Midazolam-Controlled Trial. Am J Psychiatry 178:352-  
32 362, 2021.  
33 Li W, Zhou Y, Liu W, Wang C, Lan X, Zhang Z, Zhang F, Ye Y, Liu H, Wu K, McIntyre RS, Ning Y:  
34 Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar  
35 depression: A naturalistic follow-up study. J Affect Disord 300:172-178, 2022.  
36 Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA: Maintenance ketamine  
37 treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet  
38 Psychiatry 9:907-921, 2022.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Letter to the Editor: Beyond crisis, prolonged effectiveness of ketamine in adolescents**  
4  
5  
6 **with treatment-refractory depression**  
7

8 Laura DUSI<sup>1</sup>, Alice HOFMAN<sup>2</sup>, Nawel CHERIGUI-MEFTOUT<sup>2</sup>, Anne FRANCESCHINI-  
9 MANDEL<sup>2</sup>, Julie BRUNELLE<sup>2</sup>, Philippe MAUNY<sup>2</sup>, Marine LE BOUEDEC<sup>2</sup>, Angèle CONSOLI<sup>2,3</sup>,  
10 David COHEN<sup>2,4</sup>, Antoine DELCUL<sup>5</sup>, Cyril HANIN<sup>2</sup>, Xavier BENAROUS<sup>2,3</sup>  
11  
12

13  
14 <sup>1</sup>Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

15 <sup>2</sup> Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière University Hospital, AP-HP.Sorbonne  
16 Université, Paris, France

17 <sup>3</sup> INSERM UMR-S 1136, Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLesp), Social  
18 Epidemiology, Mental Health and Addictions (ESSMA) team, Paris, France

19 <sup>4</sup> CNRS UMR 7222, Institute for Intelligent Systems and Robotics, Sorbonne University, Paris, France

20 <sup>5</sup> Department of Adult Psychiatry, Pitié-Salpêtrière University Hospital, APHP.Sorbonne Université, Paris,  
21 France

22 Running head: Ketamine depression

23 Type of article: Letters to the Editor

24  
25  
26  
27 **CORRESPONDING AUTHOR:**

28 Xavier Benarous, M.D., Ph.D.

29 Child and Adolescent Psychiatry Department

30 Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université

31 47-83 boulevard de l'Hôpital, 75013 Paris, France

32 Tel: + 33 1 42 16 23 63

33 Fax: + 33 (0) 1 42 16 19 03

34 [xavier.benarous@aphp.fr](mailto:xavier.benarous@aphp.fr)  
35

36 **Declarations**

37 **Ethics approval and consent to participate**

38 Written informed consent was obtained from the patient to publish any potentially identifiable images or data in  
39 this article. This manuscript adheres to the CARE guidelines for publishing case reports, with the completed  
40 CARE 2013 checklist attached as Supplementary Materials. Ethical committees / Internal Review Boards: not  
41 applicable

42 **Consent for Publication**

43 Written informed consent for publication was obtained from the parents and is available upon request.

44 **Availability of data and materials**

45 Data sharing does not apply to this article, as no datasets were generated during the current study.

46 **Competing interests**

47 The authors declare that they have no competing interests.

48 **Funding**

49 This research received no specific grant support.

50 **Authors' contributions**

51 LD, CH, DC and XB conceptualized and designed the study, drafted the initial manuscript, and reviewed and  
52 revised the manuscript. AH, NCM, AFM, JB, AC, PM, MLB, and AD followed the patient and contributed to  
53 data acquisition. All authors approved the final manuscript as submitted and agreed to be accountable for all  
54 aspects of the work.

55 **Acknowledgements**

56 The authors would like to thank the patient and his parents for their cooperation as well as all the staff of the care  
57 unit for their support and assistance during the patient's follow-up.

58 **Clinical trial number**

59 Not applicable  
60

1  
2  
3 **Letter to the Editor: Beyond crisis, prolonged effectiveness of ketamine in adolescents**  
4  
5 **with treatment-refractory depression**  
6  
7

8  
9 The clinical, functional, and economic burden associated with treatment-refractory  
10 depression (TRD) in adolescence makes it urgent to develop new pharmacological options.  
11 Unlike in adult psychiatry, the evidence supporting the use of ketamine in adolescents for this  
12 indication remains relatively limited, while most studies focus on suicidal crises and short-  
13 term outcomes (Dwyer et al. 2021; Smith-Apeldoorn et al. 2022). Dwyer et al. (2017)  
14 published the only report of an 8-week intravenous ketamine protocol, showing sustained  
15 clinical benefit over 30 weeks. The current clinical vignettes illustrate the prolonged  
16 effectiveness and safety of ketamine for two adolescents with TRD.  
17  
18

19 Patient A was a 14-year-old adolescent assigned female at birth and identifies as male  
20 (AFAB). A family history of type 1 bipolar disorder was reported in two family members. He  
21 was referred for severe TRD with no melancholic or psychotic features, with an onset two  
22 years ago, with severe non-suicidal self-injury (NSSI) requiring orthopedic intervention, and a  
23 suicidal attempt by jumping from his school building. Intravenous ketamine was administered  
24 at a dose of 0.25 mg/kg, subsequently increased to 0.5 mg/kg, resulting in a total of ten  
25 treatments (Figure 1). A rapid clinical improvement was observed following the initial  
26 infusion, reflected by a 45% reduction in MADRS score and complete remission by day 16.  
27 Over the next 5 months, the patient continued to show a partial decrease in depressive  
28 symptoms over this period, estimated at approximately 40–50% by the referent psychiatrist.  
29  
30

31 Patient B was a 17-year-old male. The biological parents of both siblings died when the  
32 patient was 8 months old. Developmental history found a delay in language acquisition and  
33 Attention-Deficit/Hyperactivity Disorder. The patient was initially referred for a suicidal and  
34 rage crisis, with a diagnosis of TRD with melancholic features. The patient received a total of  
35 eight ketamine infusions. A marked clinical response was observed following the first  
36 infusion, with a 77% reduction in MADRS and complete remission by day 43. One year after  
37 discharge, the patient had not required any further hospitalizations or emergency  
38 consultations. Pharmacological treatment was well tolerated, and no adverse effects were  
39 reported.  
40  
41

42  
43 [Insert Figure 1 about here]  
44

45 As the antidepressant effect of ketamine is regarded as rapid and often transient, its  
46 application beyond the scope of short-term suicidal crisis management remains less well  
47 explored, especially in adolescents. In adults, roughly half of 71 patients who completed a  
48 finite course of repeated IV ketamine maintained their improvement at nine months, with  
49 most relapses occurring within the first two weeks (Li et al. 2022).  
50  
51

52 For both patients here, a rapid and complete remission of depressive symptoms was  
53 observed. More importantly for our perspective, both patients maintained complete remission  
54 at six months (patient A) and one year (patient B) following the last ketamine infusion. The  
55 treatment was well tolerated, and no relapse was observed in the weeks following the end of  
56 the administration. Such preliminary findings stress the potential for sustained long-term  
57 clinical benefit of ketamine IV for adolescents with TRD, which represents considerable  
58 promise for these patients.  
59  
60

1  
2  
3  
4  
5 **FIGURE 1.** Decrease in MADRS score and PRN medication during patients' ketamine  
6 treatment

7  
8 *Note.* PRN was mainly prescribed to reduce agitation, sleep difficulties, and irritability-  
9 related aggressive behaviors. For patient A, after discussion with our local expert centre for  
10 bipolar disorder (BD), considering the high risk of BD in patient A (i.e., positive family  
11 history of BD, behavioral activation symptoms after SSRI prescription) we decide to not  
12 prescribe another SSRI, and to go directly to ketamine with associated prescriptions of mood  
13 stabilizers. Two months after discharge, he went to emergency department following an  
14 episode of NSSI in a context of acute stress, crisis management interventions helped the  
15 patient to quickly return to baseline functioning.  
16  
17  
18

### 19 **SUPPLEMENTARY MATERIALS.**

20 **FIG S1.** Detailed time line of treatment received by patient A.

21 **FIG S2.** Detailed time line of treatment received by patient B  
22

### 23 **REFERENCES**

- 24  
25  
26 Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH: Ketamine as a Treatment for  
27 Adolescent Depression: A Case Report. *J Am Acad Child Adolesc Psychiatry* 56:352-354,  
28 2017.  
29 Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Coulores  
30 K, Sanacora G, Bloch MH: Efficacy of Intravenous Ketamine in Adolescent Treatment-  
31 Resistant Depression: A Randomized Midazolam-Controlled Trial. *Am J Psychiatry* 178:352-  
32 362, 2021.  
33 Li W, Zhou Y, Liu W, Wang C, Lan X, Zhang Z, Zhang F, Ye Y, Liu H, Wu K, McIntyre RS, Ning Y:  
34 Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar  
35 depression: A naturalistic follow-up study. *J Affect Disord* 300:172-178, 2022.  
36 Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA: Maintenance ketamine  
37 treatment for depression: a systematic review of efficacy, safety, and tolerability. *Lancet*  
38 *Psychiatry* 9:907-921, 2022.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





Figure 1. Decrease in MADRS score and PRN medication during patients' ketamine treatment

608x534mm (96 x 96 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

